Russian generic drug manufacturer Ozon Pharmatsevtika is launching the over-the-counter drug Netugast (INN trimebutine) for functional disorders of the gastrointestinal tract and biliary tract, GxP News found out from the company.
“Stress and poor nutrition often lead to functional gastrointestinal diseases. Patients experience pain, bloating, and stool disorders, with no detected organic cause,” the pharmaceutical manufacturer’s press service notes. According to Ozon Pharmatsevtika, Netugast addresses these issues through combined effects — spasmolytic, prokinetic (normalization of gastrointestinal motility), and analgesic.
The drug does not mask acute conditions, such as appendicitis, and is approved for long-term use, the company says. As emphasized in the message, Netugast will be significantly more affordable than its analogues. The medication is planned to be released in different packaging sizes: initially, a pack of N30 (200 mg), and from February 2026 — a pack of N60 (200 mg). The statement says, “There are no analogs on the market with a similar dosage and packaging; a package is designed for a full course of treatment for functional gastrointestinal diseases.”
“Trimebutine molecule was synthesized in France back in 1969, but the trimebutine market in Russia is far from saturated. It demonstrates stable growth, driven by high efficiency, safety, and the triple action of the molecule. We plan to enter the top 3 trimebutine drugs manufactures in the Russian market,” said Ekaterina Rubtsova, Head of the portfolio No. 1 of the OTC generic brands at Ozon Pharmatsevtika.
Ozon Pharmatsevtika was founded in 2001. The company operates 16 production sites in Tolyatti and Zhigulevsk, Samara region, and maintains research laboratories in the Skolkovo biopharmaceutical cluster and Khimki. The group’s revenue in 2024 amounted to 25.6 billion rubles, with a net profit of 4.6 billion rubles.
